The FDA approved tezepelumab-ekko (TEZSPIRE; AstraZeneca/Amgen) on Friday as an add-on maintenance treatment in patients aged ...

The approval for the CRSwNP indication was based on data from the randomized, double-blind, placebo-controlled WAYPOINT trial.

AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the add-on maintenance treatment of ...

Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP ...

Amgen and AstraZeneca’s Tezspire (tezepelumab-ekko) gains FDA approval as an add-on maintenance therapy for patients aged 12 and older with inadequately controlled chronic rhinosinusitis with nasal ...

Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the add-on maintenance treatment of inadequately ...

AstraZeneca and Amgen's Tezspire (tezepelumab) has been approved in the US for the add-on maintenance treatment of adult and ...

The FDA approved Amgen's and AstraZeneca's drug to treat chronic rhinosinusitis with nasal polyps, an inflammatory condition of the sinuses and nasal passages. The companies said the approval was ...

October 2025 Tezspire approved in the US for chronic rhinosinusitis with nasal polyps Approval broadens indication for Tezspire to a second disease characterised by epithelial-driven inflammationAstra ...

Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- ...

Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with nasal polyps (CRSwNP), a second biologic therapy has broken through with a | ...

The U. Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic inflammatory sinus ...